Maurizio Paciaroni (Italy)

IRCCS MultiMedica - San Giuseppe Hospital Neurology - Stroke Unit
Professor Maurizio Paciaroni is Director of the Neurology-Stroke Unit at San Giuseppe Hospital, Milan, Italy. Professor Paciaroni has over 20 years of teaching and research experience. He received his Medicine degree from the University of Perugia where he also specialised in neurology before taking up a position at the Neurology Department of the Center Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Professor Pacironi also spent time in Canada as a Research Fellow at the Robarts Research Institute, Western University, Ontario, before returning to Italy to continue his career. Professor Paciaroni is regional coordinator (Umbria) of the Italian Stroke Organization (ISO) and international coordinator for the drafting of the European Stroke Organization guidelines on secondary stroke prophylaxis in patients with atrial fibrillation. Professor Paciarioni has been Principal Investigator and coordinator of several international studies including THALES, NAVIGATE, ESUS, SOCRATES, and ACTIMIS. Professor Paciarioni has authored over 200 scientific publications, books, and book chapters.

Author Of 3 Presentations

Case Presentation

Session Type
Meet the expert
Date
29.10.2021, Friday
Session Time
14:00 - 14:45
Room
INDUSTRY 1
Lecture Time
14:05 - 14:15

Secondary prevention of stroke in patients with stroke and TIA

Session Type
Industry Sponsored Session
Date
28.10.2021, Thursday
Session Time
13:30 - 14:30
Room
INDUSTRY 1
Lecture Time
14:05 - 14:15

SYSTEMIC THROMBOLYSIS IN PATIENTS WITH ACUTE STROKE AND ACTIVE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

Session Type
Free Communication Session
Date
29.10.2021, Friday
Session Time
15:15 - 16:45
Room
FREE COMMUNICATIONS A
Lecture Time
16:05 - 16:15

Abstract

Background and Aims

Cancer patients frequently have concomitant cerebrovascular diseases, which significantly worsen their prognosis. Prospective studies validating intravenous thrombolysis (IVT) safety profile in patients with acute ischemic stroke and active cancer are still lacking. Our aim was to evaluate efficacy and safety profile of IVT in acute ischemic stroke patients with comorbid active cancer.

Methods

We included in a meta-analysis all relevant published studies including patients with acute ischaemic stroke with or without active cancer, and receiving IVT, according to recommendations for IVT treatment for acute ischaemic stroke. The primary outcomes were all-cause mortality, any intracerebral haemorrhage and functional outcome, reported as modified Rankin Scale (mRS).

Results

ich.pngNine studies were included in the meta-analysis. IVT was not associated with a significant increase in the incidence of intracerebral haemorrhage (OR 1.00; 95%CI 0.76 – 1.33; I2 48.07%), nor with a significant increase in death for any cause (OR 1.13; 95%CI 0.90 – 1.43; I2 51.6%); furthermore, IVT did not influence mRS between cancer and non-cancemortality.pngmrs.pngr stroke patients (OR 1.00; 95%CI 0.58 – 1.71; I2 27.42%).

Conclusions

IVT seems to be safe and effective on patients affected by an ischemic stroke and concomitant cancer. Due to the low overall quality of the evidence, high-quality randomized control trials with adequate sample sizes are needed.

Hide

Presenter of 2 Presentations

Secondary prevention of stroke in patients with stroke and TIA

Session Type
Industry Sponsored Session
Date
28.10.2021, Thursday
Session Time
13:30 - 14:30
Room
INDUSTRY 1
Lecture Time
14:05 - 14:15

Case Presentation

Session Type
Meet the expert
Date
29.10.2021, Friday
Session Time
14:00 - 14:45
Room
INDUSTRY 1
Lecture Time
14:05 - 14:15